Retrospective chart review highlights treatment patterns and outcomes in patients with LR-MDS, indicating the need for more real-world data.
Background Erythropoiesis-stimulating agents (ESAs) are an established treatment for lower-risk myelodysplastic syndromes (LR-MDS). However, real-world data on the outcomes of patients with LR-MDS treated with ESAs are limited. This study describes treatment patterns and clinical outcomes in this population.
No takes yet. Share an insight, caveat, or question.
Gordan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: